Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Subcutaneous Ocaratuzumab (Fab- and Fc-engineered Anti-CD20 Monoclonal Antibody) in Patients With Previously Treated CD20+ B-Cell Malignancies

NCT01858181 is registered in ClinicalTrials.gov with Mentrik Biotech, LLC as lead sponsor.

NCT NCT01858181
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01858181 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Subcutaneous Ocaratuzumab (Fab- and Fc-engineered Anti-CD20 Monoclonal Antibody) in Patients With Previously Treated CD20+ B-Cell Malignancies
Lead sponsor
Mentrik Biotech, LLC
Phase
Phase 1
Overall status
Unknown status
Start date
January 31, 2015
Completion date
Not reported
Enrollment
9 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

previously treated cd20+ b-cell malignancies